Q1 EPS Forecast for Ascendis Pharma A/S Decreased by Analyst

Ascendis Pharma A/S (NASDAQ:ASND) – Equities research analysts at Wedbush decreased their Q1 2025 earnings estimates for Ascendis Pharma A/S in a research report issued on Wednesday, February 12th. Wedbush analyst Y. Zhong now anticipates that the biotechnology company will post earnings of ($1.76) per share for the quarter, down from their prior forecast of ($1.58). Wedbush currently has a “Outperform” rating and a $181.00 target price on the stock. The consensus estimate for Ascendis Pharma A/S’s current full-year earnings is ($7.12) per share. Wedbush also issued estimates for Ascendis Pharma A/S’s Q2 2025 earnings at ($1.24) EPS, Q3 2025 earnings at ($1.04) EPS, Q4 2025 earnings at ($0.82) EPS, FY2025 earnings at ($4.84) EPS, FY2026 earnings at ($1.75) EPS, FY2027 earnings at $2.96 EPS and FY2028 earnings at $9.17 EPS.

Other research analysts have also issued research reports about the stock. UBS Group assumed coverage on shares of Ascendis Pharma A/S in a research note on Tuesday, January 7th. They issued a “buy” rating and a $196.00 price objective on the stock. Oppenheimer dropped their price objective on shares of Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating on the stock in a research note on Friday, November 15th. JPMorgan Chase & Co. upped their price objective on shares of Ascendis Pharma A/S from $167.00 to $168.00 and gave the company an “overweight” rating in a research note on Thursday, February 13th. TD Cowen dropped their price objective on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating on the stock in a research note on Friday, November 15th. Finally, StockNews.com upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $197.36.

Ascendis Pharma A/S Price Performance

ASND stock opened at $157.17 on Monday. Ascendis Pharma A/S has a 52-week low of $111.09 and a 52-week high of $161.00. The company’s 50 day simple moving average is $133.20 and its 200-day simple moving average is $132.57. The firm has a market capitalization of $9.54 billion, a P/E ratio of -19.45 and a beta of 0.64.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.32) by $0.64.

Institutional Trading of Ascendis Pharma A/S

Several large investors have recently modified their holdings of ASND. T. Rowe Price Investment Management Inc. boosted its holdings in shares of Ascendis Pharma A/S by 54.4% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 2,725,546 shares of the biotechnology company’s stock worth $375,226,000 after buying an additional 960,504 shares during the period. Capital International Investors boosted its holdings in Ascendis Pharma A/S by 35.7% in the 4th quarter. Capital International Investors now owns 2,863,249 shares of the biotechnology company’s stock valued at $394,183,000 after purchasing an additional 753,859 shares during the period. Groupama Asset Managment bought a new stake in Ascendis Pharma A/S in the 3rd quarter valued at $60,000. RA Capital Management L.P. boosted its holdings in Ascendis Pharma A/S by 4.1% in the 4th quarter. RA Capital Management L.P. now owns 10,112,744 shares of the biotechnology company’s stock valued at $1,392,221,000 after purchasing an additional 402,316 shares during the period. Finally, Vestal Point Capital LP boosted its holdings in Ascendis Pharma A/S by 108.0% in the 4th quarter. Vestal Point Capital LP now owns 520,000 shares of the biotechnology company’s stock valued at $71,588,000 after purchasing an additional 270,000 shares during the period.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.